U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Ovarian High Grade Serous Adenocarcinoma

MedGen UID:
770894
•Concept ID:
C3642254
•
Neoplastic Process
Synonyms: High Grade Ovarian Serous Adenocarcinoma; High-Grade Ovarian Serous Adenocarcinoma; Ovarian High-Grade Serous Adenocarcinoma

Definition

A rapidly growing serous adenocarcinoma that arises from the ovary. It is characterized by the presence of high grade cytologic features and frequent mitotic figures. [from NCI]

Professional guidelines

PubMed

Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E
Nat Commun 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6. PMID: 38762636Free PMC Article
Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
Lazurko C, Linder R, Pulman K, Lennox G, Feigenberg T, Fazelzad R, May T, Zigras T
Curr Oncol 2023 Sep 3;30(9):8159-8171. doi: 10.3390/curroncol30090592. PMID: 37754507Free PMC Article
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD
Gynecol Oncol 2021 Sep;162(3):741-750. Epub 2021 Jul 8 doi: 10.1016/j.ygyno.2021.06.033. PMID: 34247767

Recent clinical studies

Etiology

ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S, Schledermann D, Herrstedt J, Østrup O, Ditzel HJ; Academy of Geriatric Cancer Research (AgeCare)
Acta Oncol 2020 Jan;59(1):40-47. Epub 2019 Sep 3 doi: 10.1080/0284186X.2019.1657941. PMID: 31478407
Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
Nishida N, Murakami F, Higaki K
Pathol Int 2016 Jun;66(6):337-42. doi: 10.1111/pin.12419. PMID: 27250113

Diagnosis

ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S, Schledermann D, Herrstedt J, Østrup O, Ditzel HJ; Academy of Geriatric Cancer Research (AgeCare)
Acta Oncol 2020 Jan;59(1):40-47. Epub 2019 Sep 3 doi: 10.1080/0284186X.2019.1657941. PMID: 31478407
Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
Nishida N, Murakami F, Higaki K
Pathol Int 2016 Jun;66(6):337-42. doi: 10.1111/pin.12419. PMID: 27250113

Therapy

ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S, Schledermann D, Herrstedt J, Østrup O, Ditzel HJ; Academy of Geriatric Cancer Research (AgeCare)
Acta Oncol 2020 Jan;59(1):40-47. Epub 2019 Sep 3 doi: 10.1080/0284186X.2019.1657941. PMID: 31478407

Prognosis

ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S, Schledermann D, Herrstedt J, Østrup O, Ditzel HJ; Academy of Geriatric Cancer Research (AgeCare)
Acta Oncol 2020 Jan;59(1):40-47. Epub 2019 Sep 3 doi: 10.1080/0284186X.2019.1657941. PMID: 31478407

Clinical prediction guides

ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S, Schledermann D, Herrstedt J, Østrup O, Ditzel HJ; Academy of Geriatric Cancer Research (AgeCare)
Acta Oncol 2020 Jan;59(1):40-47. Epub 2019 Sep 3 doi: 10.1080/0284186X.2019.1657941. PMID: 31478407
Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
Nishida N, Murakami F, Higaki K
Pathol Int 2016 Jun;66(6):337-42. doi: 10.1111/pin.12419. PMID: 27250113

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...